Kinase inhibitors
Methods of inhibiting kinases using kinase inhibitors having olefin moieties are disclosed.
1. A compound having the formula:
wherein
W is —C(O)— or S(O) 2 —;
z is 0 or 1;
X is O or N, wherein if X is O, then z is 0;
R 1 is R 7 -substituted 7H-pyrrolo[2,3-d]pyrimidin-6-yl, R 7 -substituted 7H-pyrrolo[2,3-d]pyrimidin-7-yl or R 7 -substituted pyrazolopyrimidin-1-yl;
R 7 is independently halogen, —CN, —OH, —NH 2 , —COOH, —CF 3 , R 8 -substituted or unsubstituted alkyl, R 8 -substituted or unsubstituted heteroalkyl, R 8 -substituted or unsubstituted cycloalkyl, R 8 -substituted or unsubstituted heterocycloalkyl, R 8 -substituted or unsubstituted aryl, R 8 -substituted or unsubstituted heteroaryl, or -L 6 -R 7A ;
L 6 is —O—, —C(O)—, —C(O)NH—, —S(O) m —, or —S(O) m NH—;
m is 0, 1, or 2;
R 7A is hydrogen, halogen, —CN, —OH, —NH 2 , —COOH, —CF 3 , R 8 -substituted or unsubstituted alkyl, R 8 -substituted or unsubstituted heteroalkyl, R 8 -substituted or unsubstituted cycloalkyl, R 8 -substituted or unsubstituted heterocycloalkyl, R 8 -substituted or unsubstituted aryl, or R 8 -substituted or unsubstituted heteroaryl;
R 8 is independently hydrogen, halogen, —CN, —OH, —NH 2 , —COOH, —CF 3 , R 9 -substituted or unsubstituted alkyl, R 9 -substituted or unsubstituted heteroalkyl, R 9 -substituted or unsubstituted cycloalkyl, R 9 -substituted or unsubstituted heterocycloalkyl, R 9 -substituted or unsubstituted aryl, or R 9 -substituted or unsubstituted heteroaryl;
R 9 is independently hydrogen, halogen, —CN, —OH, —NH 2 , —COOH, —CF 3 , R 10 -substituted or unsubstituted alkyl, R 10 -substituted or unsubstituted heteroalkyl, R 10 -substituted or unsubstituted cycloalkyl, R 10 -substituted or unsubstituted heterocycloalkyl, R 10 -substituted or unsubstituted aryl, or R 10 -substituted or unsubstituted heteroaryl;
R 10 is independently halogen, —CN, —OH, —NH 2 , —COOH, —CF 3 , unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, or unsubstituted heteroaryl;
R 3 and R 4 are independently hydrogen, unsubstituted alkyl, alkyl substituted with one or two hydroxy or di(unsubstituted alkyl)amino, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, or substituted or unsubstituted aryl, wherein R 3 and R 4 are optionally joined together with X to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl;
L 1 is a bond or unsubstituted phenylene;
L 4 and L 5 are independently a bond, unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene; and
wherein if L 1 is a bond and R 1 is (3-(4-amino-5-p-tolyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)propan-1-ol)-6-yl, then at least one of R 3 and R 4 are not hydrogen.
2. The compound of claim 1 , wherein X is N.
3. The compound according to claim 1 , having the structure
4. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.
5. A compound having the formula:
wherein
W is —C(O)— or —S(O) 2 —;
z is 1;
R 1 is R 7 -substituted 7H-pyrrolo[2,3-d]pyrimidin-6-yl, R 7 -substituted 7H-pyrrolo[2,3-d]pyrimidin-7-yl or R 7 -substituted pyrazolopyrimidin-1-yl;
R 7 is halogen, —CN, —OH, —NH 2 , —COOH, —CF 3 , R 8 -substituted or unsubstituted alkyl, R 8 -substituted or unsubstituted heteroalkyl, R 8 -substituted or unsubstituted cycloalkyl, R 8 -substituted or unsubstituted heterocycloalkyl, R 8 -substituted or unsubstituted aryl, R 8 -substituted or unsubstituted heteroaryl, or -L 6 -R 7A ;
L 6 is —O—, —C(O)—, —C(O)NH—, —S(O) m —, or —S(O) m NH—;
m is 0, 1, or 2;
R 7A is hydrogen, halogen, —CN, —OH, —NH 2 , —COOH, —CF 3 , R 8 -substituted or unsubstituted alkyl, R 8 -substituted or unsubstituted heteroalkyl, R 8 -substituted or unsubstituted cycloalkyl, R 8 -substituted or unsubstituted heterocycloalkyl, R 8 -substituted or unsubstituted aryl, or R 8 -substituted or unsubstituted heteroaryl;
R 8 is independently hydrogen, halogen, —CN, —OH, —NH 2 , —COOH, —CF 3 , R 9 -substituted or unsubstituted alkyl, R 9 -substituted or unsubstituted heteroalkyl, R 9 -substituted or unsubstituted cycloalkyl, R 9 -substituted or unsubstituted heterocycloalkyl, R 9 -substituted or unsubstituted aryl, or R 9 -substituted or unsubstituted heteroaryl;
R 9 is independently hydrogen, halogen, —CN, —OH, —NH 2 , —COOH, —CF 3 , R 10 -substituted or unsubstituted alkyl, R 10 -substituted or unsubstituted heteroalkyl, R 10 -substituted or unsubstituted cycloalkyl, R 10 -substituted or unsubstituted heterocycloalkyl, R 10 -substituted or unsubstituted aryl, or R 10 -substituted or unsubstituted heteroaryl;
R 10 is independently halogen, —CN, —OH, —NH 2 , —COOH, —CF 3 , unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, or unsubstituted heteroaryl;
R 3 and R 4 are independently hydrogen, unsubstituted alkyl, alkyl substituted with one or two hydroxy or di-(unsubstituted alkyl)amino, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, or substituted or unsubstituted aryl wherein R 3 and R 4 are optionally joined together with X to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl;
L 1 is a bond or unsubstituted phenylene;
L 4 and L 5 are independently a bond, unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene; and
wherein if L 1 is a bond and R 1 is (3-(4-amino-5-p-tolyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)propan-1-ol)-6-yl, then at least one of R 3 and R 4 are not hydrogen.
6. The compound according to claim 5 , wherein R 1 is R 7 -substituted 7H-pyrrolo[2,3-d]pyrimidinyl.
7. The compound according to claim 6 , wherein R 3 and R 4 are hydrogen.
8. The compound according to claim 6 ,
wherein
R 3 is unsubstituted alkyl; and
R 4 is hydrogen.
9. The compound according to claim 6 , wherein R 3 and R 4 join with N to form R 23 -substituted or unsubstituted pyrrolidinyl.
10. The compound according to claim 5 ,
wherein
R 1 is R 7 -substituted 7H-pyrrolo[2,3-d]pyrimidinyl; and
R 7 is —NH 2 , R 8 -substituted or unsubstituted alkyl, or R 8 -substituted or unsubstituted phenyl.